0000818686 False 0000818686 2024-07-31 2024-07-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM 8-K
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 31, 2024
_______________________________
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
(Exact name of registrant as specified in its charter)
_______________________________
| Israel | 001-16174 | Not Applicable |
| (State or other jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification Number) |
124 Dvora Hanevi’a Street
Tel Aviv 6944020, Israel
(Address of Principal Executive Offices, including Zip Code)
+972-3-914-8213
(Registrant's Telephone Number, including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
_______________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| American Depositary Shares, each representing one Ordinary Share | TEVA | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On July 31, 2024, Teva Pharmaceutical Industries Ltd. issued a press release announcing its financial results for the period ended June 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and the information contained therein is incorporated herein by reference.
The information included in this Item 2.02 is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | TEVA PHARMACEUTICAL INDUSTRIES LIMITED |
| | | |
| | | |
| Date: July 31, 2024 | By: | /s/ Eli Kalif |
| | | Eli Kalif |
| | | Executive Vice President, Chief Financial Officer |
| | | |
EXHIBIT 99.1
Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All
Regions and AUSTEDO®; Raises 2024 Financial Guidance
For an accessible version of this Press Release, please visit www.tevapharm.com
- Q2 2024 revenues of $4.2 billion reflecting an increase of 7% in U.S. dollars or 11% in local currency
terms compared to Q2 2023.
- Generics business grows across all regions – increased in local currency terms by 16% in the U.S.,
8% in Europe and 22% in International Markets, compared to Q2 2023.
- AUSTEDO – continued growth, U.S. revenue of $407 million in Q2 2024, an increase of 32% compared
to Q2 2023; raising 2024 revenue outlook to ~$1.6 billion.
- AJOVY® – global revenues of $115 million in Q2 2024, an increase of 12% in local
currency terms compared to Q2 2023.
- Announced acceleration of development timeline for duvakitug (Anti-TL1A) – top-line results now expected
in Q4 2024, with full data expected next year.
- Announced positive Phase 3 efficacy results for olanzapine LAI (TEV' 749); so far completed ~95% of target
injections with no PDSS observed.
- SIMLANDI® (adalimumab-ryvk) injection launched in May 2024 as an interchangeable biosimilar
to Humira®.
- SELARSDI™ (ustekinumab-aekn) injection for subcutaneous use, preparing for February 2025 launch
as a biosimilar to Stelara®.
Q2 2024 Highlights:
- Revenues of $4.2 billion
- GAAP loss per share of $0.75
- Non-GAAP diluted EPS of $0.61
- Cash flow generated from operating activities of $103 million
- Free cash flow of $324 million
- Building on Teva's strong performance in the first half of2024 and expected developments in the second
half of the year, Teva's full year 2024 business outlook is raised to:
- Revenues of $16.0 - $16.4 billion
- AUSTEDO revenues of ~$1.6 billion
- Adjusted EBITDA of $4.6 - $5.0 billion
- Non-GAAP diluted EPS of $2.30 - $2.50
TEL AVIV, Israel, July 31, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results
for the quarter ended June 30, 2024.
Mr. Richard Francis, Teva's President and CEO, said, "In the second quarter of 2024,
we are encouraged by the positive momentum across each of the four pillars of our Pivot to Growth strategy. Teva's global revenues of
$4.2 billion increased by 7% in U.S. dollars, or 11% in local currency terms compared to the second quarter of 2023, delivering strong
growth driven mainly by our generics and innovative business, with AUSTEDO growing 32% in the U.S. compared to Q2 2023."
Mr. Francis continued, "We are also showing significant progress in on our late-stage innovative pipeline, underscored by the acceleration
of the development timeline of duvakitug (Anti-TL1A), with top-line results now expected in the fourth quarter of 2024, and full data
expected next year.
"With these robust results, we are raising our financial guidance for 2024."
Pivot to Growth Strategy
In May 2023, we introduced our “Pivot to Growth” strategy, which is based on four key pillars: (i) delivering on our growth
engines, mainly AUSTEDO, AJOVY, UZEDY® and our late-stage pipeline of biosimilars; (ii) stepping up innovation through
delivering on our late-stage innovative pipeline assets as well as building up our early-stage pipeline organically and potentially through
business development activities; (iii) sustaining our generics medicines powerhouse with a global commercial footprint, focused portfolio,
pipeline and manufacturing footprint; and (iv) focusing our business by optimizing our portfolio and global manufacturing footprint to
enable strategic capital deployment to accelerate our near and long-term growth engines and reorganizing certain of our business units
to a more optimal structure, while also reorganizing key business units to enhance operational efficiency.
Second Quarter 2024 Consolidated Results(1)
Revenues in the second quarter of 2024 were $4,164 million, an increase of 7% in U.S. dollars or 11% in local currency
terms compared to the second quarter of 2023. This increase was mainly due to higher revenues from generic products in all our segments,
and from AUSTEDO in our United States and International Markets segments.
Exchange rate movements during the second quarter of 2024, including hedging effects, negatively impacted overall
revenues by $122 million compared to the second quarter of 2023. Exchange rate movements during the second quarter of 2024, including
hedging effects, negatively impacted our operating income and non-GAAP operating income each by $56 million compared to the second quarter
of 2023.
Gross profit in the second quarter of 2024 was $2,024 million, an increase of 13% compared to $1,796 million in the
second quarter of 2023. Gross profit margin was 48.6% in the second quarter of 2024, compared to 46.3% in the second
quarter of 2023. Non-GAAP gross profit was $2,205 million in the second quarter of 2024, an increase of 9% compared to
$2,023 million in the second quarter of 2023. Non-GAAP gross profit margin was 52.9% in the second quarter
of 2024, compared to 52.2% in the second quarter of 2023. The increase in both gross profit margin and non-GAAP gross profit margin was
mainly due to a favorable mix of products, primarily driven by growth in AUSTEDO revenues.
Research and Development (R&D) expenses, net in the second quarter of 2024 were $269 million,
an increase of 12% compared to $240 million in the second quarter of 2023 as we continue to execute on our Pivot to Growth Strategy. Our
higher R&D expenses, net in the second quarter of 2024, compared to the second quarter of 2023, were mainly due to an increase related
to our late-stage innovative pipeline in immunology, as well as related to immuno-oncology and neuroscience projects.
Selling and Marketing (S&M) expenses in the second quarter of 2024 were $656 million, an increase of 9% compared
to the second quarter of 2023. This increase was mainly due to promotional activities in our innovative products.
General and Administrative (G&A) expenses in the second quarter of 2024 were $283 million, a decrease of 8% compared
to the second quarter of 2023, mainly due to lower litigation costs in the second quarter of 2024.
Other income in the second quarter of 2024 was $2 million, compared to $33 million in the second quarter of 2023.
Other income in the second quarter of 2023 included a capital gain from the sale of assets related to our International Markets segment.
Operating loss in the second quarter of 2024 was $5 million, compared to an operating loss of $654
million in the second quarter of 2023. Operating loss as a percentage of revenues was 0.1% in the second quarter of 2024, compared to
16.9% of revenues in the second quarter of 2023. The higher operating loss in the second quarter of 2023 was mainly due to higher legal
settlements and loss contingencies as well as higher goodwill impairment charges. Non-GAAP operating income in the second
quarter of 2024 was $1,056 million representing a non-GAAP operating margin of 25.3% compared to non-GAAP operating income of $1,011 million
representing a non-GAAP operating margin of 26.1% in the second quarter of 2023. The decrease in non-GAAP operating margin in the second
quarter of 2024 was mainly due to higher operational expenses as a percentage of revenues, partially offset by higher gross profit margin.
Financial expenses, net in the second quarter of 2024 were $241 million, mainly comprised of net-interest expenses
of $233 million. In the second quarter of 2023, financial expenses, net were $268 million, mainly comprised of net-interest expenses of
$240 million.
In the second quarter of 2024, we recognized a tax expense of $630 million, on a pre-tax loss of $246 million. Our
tax rate for the second quarter of 2024 was mainly affected by a settlement agreement with the Israeli Tax Authorities (“ITA”)
and impairments. The settlement agreement with the ITA resulted in an increase of $506 million in Teva's total income taxes in the second
quarter of 2024, as certain elements had been recognized in previous periods. For additional information on the settlement agreement,
see our Current Report on Form 8-K filed with the SEC on June 25, 2024. In the second quarter of 2023, we recognized a tax benefit of
$16 million, on a pre-tax loss of $923 million. Our tax rate for the second quarter of 2023 was mainly affected by impairments, legal
settlements, amortization, and interest expense disallowances. Non-GAAP tax rate in the second quarter
of 2024 was 15.4%, compared to 15.2% in the second quarter of 2023. Our non-GAAP tax rate in the second quarter of 2024 was mainly affected
by the generation of profits in various jurisdictions with different tax rates, tax benefits in Israel and other countries, as well as
infrequent or non-recurring items. Our non-GAAP tax rate in the second quarter of 2023 was mainly affected by the generation of profits
in various jurisdictions with different tax rates, interest expense disallowances, tax benefits in Israel and other countries, as well
as infrequent or non-recurring items.
We expect our annual non-GAAP tax rate for 2024 to be between 14%-17%, higher than our non-GAAP tax rate for 2023, which was 13%, mainly
due to a reduced net tax benefit related to deferred tax resulting from intellectual property related integration plans in 2024 compared
to 2023.
Net loss attributable to Teva and loss per share in the second quarter of 2024 were $846 million
and $0.75, respectively, compared to net loss attributable to Teva and loss per share of $872 million and $0.78, respectively, in the
second quarter of 2023. The lower net loss in the second quarter of 2024 was mainly due to lower operating loss, partially offset by higher
income taxes, as discussed above. Non-GAAP net income attributable to Teva and non-GAAP diluted earnings
per share in the second quarter of 2024 were $697 million and $0.61, respectively, compared to $629 million and $0.56, respectively,
in the second quarter of 2023.
Adjusted EBITDA was $1,168 million in the second quarter of 2024, an increase of 4%, compared to $1,125 million in
the second quarter of 2023.
As of June 30, 2024 and 2023, the fully diluted share count for purposes of calculating our market capitalization
was approximately 1,167 million shares and 1,157 million shares, respectively.
Non-GAAP information: net non-GAAP adjustments in the second quarter of 2024 were $1,542 million. Non-GAAP net income
attributable to Teva and non-GAAP diluted EPS for the second quarter of 2024 were adjusted to exclude the following items:
- Amortization of purchased intangible assets of $146 million, of which $135 million is included in cost of sales and the remaining
$11 million in S&M expenses;
- Impairment of long-lived assets of $130 million;
- Goodwill impairment charge of $400 million related to the Teva API reporting unit;
- Legal settlements and loss contingencies of $83 million;
- Contingent consideration expenses of $192 million, which primarily consisted of $174 million related to a change in the estimated
future royalty payments to Allergan in connection with lenalidomide capsules (the generic version of Revlimid®);
- Equity compensation expenses of $32 million;
- Restructuring expenses of $18million;
- Financial expenses of $12 million;
- Other non-GAAP items of $59 million;
- Items attributable to non-controlling interests of$33 million; and
- Corresponding tax effects and unusual tax items of $503 million, of which $495 million is related to the settlement agreement with
the ITA discussed above.
We believe that excluding such items facilitates investors’ understanding of our business including underlying performance trends,
thereby improving the comparability of our business performance results between reporting periods.
For a reconciliation of the U.S. GAAP results to the adjusted non-GAAP figures and for additional information, see the tables below
and the information included under “Non-GAAP Financial Measures.” Investors should consider non-GAAP financial measures in
addition to, and not as replacement for, or superior to, measures of financial performance prepared in accordance with GAAP.
Cash flow generated from operating activities during the second quarter of 2024 was $103 million, compared to $324
million of cash flow generated from operating activities in the second quarter of 2023. The lower cash flow generated from operating activities
in the second quarter of 2024 resulted mainly from changes in working capital items, including a negative impact from accounts receivables,
net of SR&A, driven mainly from higher sales during the second quarter of 2024 with extended payment terms into the third quarter,
and from accounts payables, as well as higher tax payments.
During the second quarter of 2024, we generated free cash flow of $324 million, which we define as comprising $103
million in cash flow generated from operating activities, $317 million in beneficial interest collected in exchange for securitized accounts
receivables (under our EU securitization program) and $1 million in divestitures of businesses and other assets, partially offset by $97
million in cash used for capital investment. During the second quarter of 2023, we generated free cash flow of $632 million, which we
define as comprising $324 million in cash flow generated from operating activities, $371 million in beneficial interest collected in exchange
for securitized accounts receivables (under our EU securitization program) and $56 million in proceeds from divestitures of businesses
and other assets, partially offset by $119 million in cash used for capital investment. The decrease in free cash flow in the second quarter
of 2024, resulted mainly from lower cash flow generated from operating activities, as well as lower proceeds from divestitures of businesses
and other assets.
As of June 30, 2024, our debt was $18,640 million, compared to $19,833 million as of December 31, 2023. This decrease
was mainly due to repayment of $956 million of 6% senior notes at maturity and a positive impact of $247 million from exchange rate fluctuations.
The portion of total debt classified as short-term as of June 30, 2024 was 11% compared to 8% as of December 31, 2023. Our average debt
maturity was approximately 5.8 years as of June 30, 2024, compared to 6.0 years as of December 31, 2023.
_________
(1) The data presented in this press release with respect to comparative periods include revised figures. For additional
information, see note 1b to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December
31, 2023 and note 1c to our consolidated financial statements included in our Quarterly Report on Form 10-Q for the period ended June
30, 2024.
Segment Results for the Second Quarter of 2024
United States Segment
As part of the previously announced shift in executive management responsibilities and in line with our Pivot to Growth strategy, commencing
January 1, 2024, Canada is reported as part of our International Markets segment. Prior period amounts were recast to reflect this change.
The following table presents revenues, expenses and profit for our United States segment for the three months ended June 30, 2024 and
2023:
| |
Three
months ended June 30, |
| |
2024 |
|
2023 |
| |
(U.S. $ in millions / % of Segment
Revenues) |
| Revenues |
$ |
2,110 |
100% |
$ |
1,892 |
100% |
| Gross profit |
|
1,167 |
55.3% |
|
1,017 |
53.8% |
| R&D expenses |
|
170 |
8.1% |
|
156 |
8.2% |
| S&M expenses |
|
270 |
12.8% |
|
250 |
13.2% |
| G&A expenses |
|
100 |
4.7% |
|
101 |
5.3% |
| Other income |
|
(1) |
§ |
|
(1) |
§ |
| Segment profit* |
$ |
629 |
29.8% |
$ |
511 |
27.0% |
| |
|
|
|
|
|
|
* Segment profit does not include amortization and certain other items.
§ Represents
an amount less than 0.5%.
|
| |
Revenues from our United States segment in the second quarter of 2024 were $2,110 million, an increase of $218 million,
or 12%, compared to the second quarter of 2023. This increase was mainly due to higher revenues from generic products, AUSTEDO and COPAXONE®,
partially offset by lower revenues from certain innovative products, primarily BENDEKA® and TREANDA®,
as well as from Anda, our distribution business.
Revenues by Major Products and Activities
The following table presents revenues for our United States segment by major products and activities for the three months ended June
30, 2024 and 2023:
| |
|
|
|
|
| |
|
Three
months ended
June 30, |
|
Percentage Change |
| |
|
2024 |
|
2023 |
|
2024-2023 |
| |
|
(U.S.
$ in millions) |
|
|
| |
|
|
|
|
|
|
|
|
| Generic products |
|
$ |
1,023 |
|
$ |
884 |
|
16% |
| AJOVY |
|
|
42 |
|
|
52 |
|
(20%) |
| AUSTEDO |
|
|
407 |
|
|
308 |
|
32% |
| BENDEKA and TREANDA |
|
|
41 |
|
|
67 |
|
(39%) |
| COPAXONE |
|
|
81 |
|
|
56 |
|
44% |
| Anda |
|
|
373 |
|
|
392 |
|
(5%) |
| Other |
|
|
144 |
|
|
131 |
|
9% |
| Total |
|
$ |
2,110 |
|
$ |
1,892 |
|
12% |
| |
|
|
|
|
|
|
|
|
Generic products revenues in our United States segment (including biosimilars) in the second quarter of 2024 were
$1,023 million, an increase of 16% compared to the second quarter of 2023, the majority of which was driven by higher revenues from lenalidomide
capsules (the generic version of Revlimid®), and the remaining primarily by the launch of liraglutide injection 1.8mg
(an authorized generic of Victoza®), partially offset by increased competition to other generic products.
Among the most significant generic products we sold in the United States in the second quarter of 2024 were lenalidomide capsules (the
generic version of Revlimid®), epinephrine injectable solution (the generic version of EpiPen® and EpiPen
Jr®), liraglutide injection (an authorized generic of Victoza®), and Truxima® (the biosimilar
to Rituxan®). In the second quarter of 2024, our total prescriptions were approximately 303 million (based on trailing
twelve months), representing 7.9% of total U.S. generic prescriptions, compared to approximately 319 million (based on trailing twelve
months), representing 8.4% of total U.S. generic prescriptions in the second quarter of 2023, all according to IQVIA data.
On February 24, 2024, Alvotech and Teva announced that the FDA approved SIMLANDI (adalimumab-ryvk)
injection, as an interchangeable biosimilar to Humira®, for the treatment of adult rheumatoid arthritis, juvenile
idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult
plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. On April 17, 2024, Alvotech and Teva amended their collaboration agreement
to enable the purchase by Quallent of a private label adalimumab-ryvk injection from Alvotech for the U.S. market, with Alvotech sharing
profits with Teva on the private label sales. On May 20, 2024, Alvotech and Teva announced that SIMLANDI is available in the United States.
On April 16, 2024, Alvotech and Teva announced that the FDA has approved SELARSDI (ustekinumab-aekn)
injection for subcutaneous use, as a biosimilar to Stelara®, for the treatment of moderate to severe plaque psoriasis
and for active psoriatic arthritis in adults and pediatric patients six years and older.
On June 24, 2024, Teva announced the launch of liraglutide injection 1.8mg (an authorized generic of Victoza®)
in the United States. Liraglutide injection is indicated to improve glycemic control in adults and pediatric patients aged 10 years and
older with type 2 diabetes mellitus and reduce the risk of cardiovascular events in adults with type 2 diabetes mellitus and established
cardiovascular disease.
AJOVY revenues in our United States segment in the second quarter of 2024 were $42 million, a decrease of 20% compared
to $52 million in the second quarter of 2023, mainly due to an increase in sales allowance due to a non-recurring item, partially offset
by higher demand. In the second quarter of 2024, AJOVY’s exit market share in the United States in terms of total number of prescriptions
was 28.6% compared to 25.1% in the second quarter of 2023.
AUSTEDO revenues in our United States segment in the second quarter of 2024 increased by 32%, to $407 million, compared
to $308 million in the second quarter of 2023, mainly due to growth in volume, as well as expanded access for patients and increased investment
to support higher demand.
AUSTEDO XR (deutetrabenazine) extended-release tablets was approved by the FDA on February 17, 2023, and became commercially available
in the U.S. in May 2023. In May 2024, the FDA approved AUSTEDO XR as a one pill, once-daily treatment option in doses of 30, 36, 42, and
48 mg. In July 2024, the FDA approved the 18 mg dosage for AUSTEDO XR making it a one pill, once-daily for all available doses. AUSTEDO
XR is a once-daily formulation indicated in adults for tardive dyskinesia and chorea associated with Huntington’s disease, which
is additional to the currently marketed twice-daily AUSTEDO. AUSTEDO XR is protected by ten Orange Book patents expiring between 2031
and 2041.
UZEDY (risperidone) extended-release injectable suspension was approved by the FDA on April 28, 2023 for the treatment
of schizophrenia in adults, and was launched in the U.S. in May 2023. UZEDY is a subcutaneous, long-acting formulation of risperidone
that controls the steady release of risperidone. UZEDY is protected by nine Orange Book patents expiring between 2025 and 2033. We are
moving forward with plans to launch UZEDY in other countries around the world. UZEDY faces competition from multiple other products.
BENDEKA and TREANDA combined revenues in our United States segment in the second quarter of 2024
were $41 million, a decrease of 39% compared to $67 million in the second quarter of 2023, mainly due to generic bendamustine products
entry into the market. The orphan drug exclusivity that had attached to bendamustine products expired in December 2022.
COPAXONE revenues in our United States segment in the second quarter of 2024 were $81 million, an increase of 44%
compared to $56 million in the second quarter of 2023, mainly due to a decrease in sales allowance due to a non-recurring item.
Anda revenues from third-party products in our United States segment in the second quarter of 2024 were $373 million,
a decrease of 5% compared to $392 million in the second quarter of 2023, mainly due to lower demand in the second quarter of 2024. Anda,
our distribution business in the United States, distributes generic and innovative medicines and OTC pharmaceutical products from Teva
and various third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals and physician offices in the
United States. Anda is able to compete in the distribution market by maintaining a broad portfolio of products, competitive pricing and
delivery throughout the United States.
United States Gross Profit
Gross profit from our United States segment in the second quarter of 2024 was $1,167 million, an
increase of 15%, compared to $1,017 million in the second quarter of 2023.
Gross profit margin for our United States segment in the second quarter of 2024 increased to 55.3%, compared to 53.8%
in the second quarter of 2023. This increase was mainly due to a favorable mix of products primarily driven by higher revenues from lenalidomide
capsules (the generic version of Revlimid®) and AUSTEDO.
United States Profit
Profit from our United States segment consists of gross profit less R&D expenses, S&M expenses, G&A expenses and any other
income related to this segment. Segment profit does not include amortization and certain other items.
Profit from our United States segment in the second quarter of 2024 was $629 million, an increase of 23% compared
to $511 million in the second quarter of 2023. This increase was mainly due to higher gross profit, partially offset by higher operational
expenses.
Europe Segment
Our Europe segment includes the European Union, the United Kingdom and certain other European countries.
The following table presents revenues, expenses and profit for our Europe segment for the three months ended June 30, 2024 and 2023:
| |
Three
months ended June 30, |
| |
2024 |
|
2023 |
| |
(U.S. $ in millions / % of Segment
Revenues) |
| Revenues |
$ |
1,213 |
100% |
$ |
1,163 |
100% |
| Gross profit |
|
677 |
55.8% |
|
640 |
55.0% |
| R&D expenses |
|
62 |
5.1% |
|
53 |
4.5% |
| S&M expenses |
|
209 |
17.2% |
|
194 |
16.7% |
| G&A expenses |
|
64 |
5.3% |
|
61 |
5.2% |
| Other income |
|
§ |
§ |
|
(1) |
§ |
| Segment profit* |
$ |
342 |
28.2% |
$ |
334 |
28.7% |
| ___________ |
|
|
|
|
|
|
* Segment profit does not include amortization and certain other items.
§ Represents
an amount less than $0.5 million or 0.5%, as applicable.
|
| |
Revenues from our Europe segment in the second quarter of 2024 were $1,213 million, an increase of 4%, or $50 million,
compared to the second quarter of 2023. In local currency terms, revenues increased by 5% compared to the second quarter of 2023, mainly
due to higher revenues from generic products and AJOVY.
Revenues by Major Products and Activities
The following table presents revenues for our Europe segment by major products and activities for the three months ended June 30, 2024
and 2023:
| |
|
Three
months ended
June 30, |
|
Percentage
Change |
| |
|
2024 |
|
2023 |
|
2024-2023 |
| |
|
(U.S.
$ in millions) |
|
|
| Generic products |
|
$ |
970 |
|
$ |
909 |
|
7% |
| AJOVY |
|
|
52 |
|
|
39 |
|
33% |
| COPAXONE |
|
|
53 |
|
|
60 |
|
(11%) |
| Respiratory products |
|
|
57 |
|
|
66 |
|
(14%) |
| Other |
|
|
81 |
|
|
89 |
|
(10%) |
| Total |
|
$ |
1,213 |
|
$ |
1,163 |
|
4% |
| |
|
|
|
|
|
|
|
|
Generic products revenues (including OTC and biosimilar products) in our Europe segment in the second quarter of 2024,
increased by 7% to $970 million, compared to the second quarter of 2023. In local currency terms, revenues increased by 8%, mainly due
to price increases as a result of market conditions such as inflationary pressures in certain markets, as well as higher revenues from
recently launched products.
AJOVY revenues in our Europe segment in the second quarter of 2024 increased by 33% to $52 million, compared to $39
million in the second quarter of 2023. In local currency terms revenues increased by 34%, mainly due to growth in European countries in
which AJOVY had previously been launched.
COPAXONE revenues in our Europe segment in the second quarter of 2024 were $53 million, a decrease of 11% compared
to the second quarter of 2023. In local currency terms, revenues decreased by 9%, due to price reductions and a decline in volume resulting
from competing glatiramer acetate products and availability of alternative therapies.
Respiratory products revenues in our Europe segment in the second quarter of 2024 were $57 million, a decrease of
14% compared to the second quarter of 2023. In local currency terms, revenues decreased by 13% compared to the second quarter of 2023,
mainly due to net price reductions and lower volumes.
Europe Gross Profit
Gross profit from our Europe segment in the second quarter of 2024 was $677 million, an increase of 6% compared to
$640 million in the second quarter of 2023.
Gross profit margin for our Europe segment in the second quarter of 2024 increased to 55.8%, compared to 55.0% in
the second quarter of 2023. This increase was mainly due to price increases of generic products as a result of market conditions such
as inflationary pressures in certain markets.
Europe Profit
Profit from our Europe segment consists of gross profit less R&D expenses, S&M expenses, G&A expenses and any other income
related to this segment. Segment profit does not include amortization and certain other items.
Profit from our Europe segment in the second quarter of 2024 was $342 million, an increase of 2%, compared to $334
million in the second quarter of 2023. This increase was mainly due to higher gross profit, as described above.
International Markets Segment
Our International Markets segment includes all countries in which we operate other than the United States and the countries included
in our Europe segment. The International Markets segment includes more than 35 countries, covering a substantial portion of the global
pharmaceutical industry.
As part of the previously announced recent shift in executive management responsibilities, commencing January 1, 2024, Canada is reported
under our International Markets segment and is no longer included as part of our United States segment. Prior period amounts were recast
to reflect this change.
The following table presents revenues, expenses and profit for our International Markets segment for the three months ended June 30,
2024 and 2023:
| |
Three
months ended June 30, |
| |
2024 |
|
2023 |
| |
(U.S. $ in millions / % of Segment
Revenues) |
| Revenues |
$ |
593 |
100% |
$ |
578 |
100% |
| Gross profit |
|
286 |
48.3% |
|
283 |
49.0% |
| R&D expenses |
|
30 |
5.1% |
|
23 |
4.0% |
| S&M expenses |
|
145 |
24.5% |
|
125 |
21.6% |
| G&A expenses |
|
38 |
6.4% |
|
34 |
5.9% |
| Other income |
|
§ |
§ |
|
(31) |
(5.4%) |
| Segment profit* |
$ |
73 |
12.3% |
$ |
132 |
22.8% |
| __________ |
|
|
|
|
|
|
* Segment profit does not include amortization and certain other items.
§ Represents
an amount less than $0.5 million or 0.5%, as applicable.
|
| |
Revenues from our International Markets segment in the second quarter of 2024 were $593 million, an increase of 3%
compared to the second quarter of 2023. In local currency terms, revenues increased by 22% compared to the second quarter of 2023, mainly
due to higher revenues from generic products in most markets, partially offset by regulatory price reductions and generic competition
to off-patented products in Japan.
In the second quarter of 2024, revenues were negatively impacted by exchange rate fluctuations of $114 million, including hedging effects,
compared to the second quarter of 2023. Revenues in the second quarter of 2024 included $5 million from a negative hedging impact, compared
to a positive hedging impact of $5 million in the second quarter of 2023, which are included in “Other” in the table below.
Revenues by Major Products and Activities
The following table presents revenues for our International Markets segment by major products and activities for the three months ended
June 30, 2024 and 2023:
| |
|
Three
months ended
June 30, |
|
Percentage
Change |
| |
|
2024 |
|
2023 |
|
2024-2023 |
| |
|
(U.S.
$ in millions) |
|
|
| Generic products |
|
$ |
486 |
|
$ |
478 |
|
2% |
| AJOVY |
|
|
22 |
|
|
14 |
|
58% |
| COPAXONE |
|
|
14 |
|
|
17 |
|
(20%) |
| Other |
|
|
71 |
|
|
69 |
|
2% |
| Total |
|
$ |
593 |
|
$ |
578 |
|
3% |
| |
Generic products revenues (including OTC and biosimilar products) in our International Markets segment were $486 million
in the second quarter of 2024, an increase of 2% compared to the second quarter of 2023. In local currency terms, revenues increased by
22% compared to the second quarter of 2023, mainly due to higher revenues in most markets, largely driven by price increases as a result
of higher costs due to inflationary pressure in certain markets and higher volumes, partially offset by regulatory price reductions and
generic competition to off-patented products in Japan.
AJOVY revenues in our International Markets segment in the second quarter of 2024 were $22 million, compared to $14
million in the second quarter of 2023. AJOVY was launched in certain markets in our International Markets segment, including in Canada,
Japan, Australia, Israel, South Korea, Brazil and others.
COPAXONE revenues in our International Markets segment in the second quarter of 2024 were $14 million compared to
$17 million in the second quarter of 2023.
AUSTEDO was launched in China and Israel in 2021 and in Brazil in 2022, for the treatment of chorea associated with
Huntington’s disease and for the treatment of tardive dyskinesia. In February 2024, we announced a strategic partnership for the
marketing and distribution of AUSTEDO in China. We continue with additional submissions in various other markets.
International Markets Gross Profit
Gross profit from our International Markets segment in the second quarter of 2024 was $286 million, an increase of
1% compared to $283 million in the second quarter of 2023.
Gross profit margin for our International Markets segment in the second quarter of 2024 decreased to 48.3%, compared
to 49.0% in the second quarter of 2023. This decrease was mainly due to a negative hedging impact, regulatory price reductions and generic
competition to off-patented products in Japan, as well as higher costs due to inflationary and other macroeconomic pressures, partially
offset by price increases largely as a result of inflationary pressures in certain markets and a favorable mix of products.
International Markets Profit
Profit from our International Markets segment consists of gross profit less R&D expenses, S&M expenses, G&A expenses and
any other income related to this segment. Segment profit does not include amortization and certain other items.
Profit from our International Markets segment in the second quarter of 2024 was $73 million, a decrease of 45%, compared to $132 million
in the second quarter of 2023. This decrease was mainly due to lower other income as well as higher S&M expenses in the second quarter
of 2024.
Other Activities
We have other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an out-licensing
platform offering a portfolio of products to other pharmaceutical companies through our affiliate Medis. Our other activities are not
included in our United States, Europe or International Markets segments described above.
On January 31, 2024, we announced that we intend to divest our API business (including its R&D, manufacturing and commercial activities)
through a sale, which divestment is expected to be completed in the first half of 2025. The intention to divest is in alignment with our
Pivot to Growth strategy. However, there can be no assurance regarding the ultimate timing or structure of a potential divestiture or
that a divestiture will be agreed or completed at all.
Revenues from other activities in the second quarter of 2024 were $249 million, an increase of 2% in U.S. dollars
and in local currency terms, compared to the second quarter of 2023.
API sales to third parties in the second quarter of 2024 were $151 million, reflecting an increase of 5% in both U.S. dollars and local
currency terms, compared to the second quarter of 2023, following a reallocation of an immaterial business within our other activities,
in line with our intention to divest our API business.
Outlook for 2024 Non-GAAP Results
| $ billions,
except EPS or as noted |
July 2024
Outlook |
January
2024 Outlook |
| Revenues* |
$16.0 - $16.4 |
$15.7
- $16.3 |
| AUSTEDO ($m)* |
~1,600 |
~1,500 |
| AJOVY ($m)* |
~500 |
~500 |
| UZEDY ($m)* |
~80 |
~80 |
| COPAXONE ($m)* |
~450 |
~400 |
| Operating Income |
4.1 - 4.5 |
4.0 - 4.5 |
| Adjusted EBITDA |
4.6 - 5.0 |
4.5 - 5.0 |
| Finance Expenses ($m) |
~1,000 |
~1,000 |
| Tax Rate |
14% - 17% |
14% - 17% |
| Diluted EPS ($) |
2.30 - 2.50 |
2.20 - 2.50 |
| Free Cash Flow** |
1.7 - 2.0 |
1.7 - 2.0 |
| CAPEX* |
~0.5 |
~0.5 |
| Foreign Exchange |
Volatile swings in FX can negatively impact revenue and income |
* Revenues and CAPEX presented on a GAAP basis.
** Free Cash Flow includes cash flow generated from operating activities net of capital expenditures and deferred purchase price cash
component collected for securitized trade receivables
Conference Call
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter
2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live
webcast on the same day, at 8:00 a.m. ET.
In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.
A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations
Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader with a category-defying portfolio, harnessing
our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of
modern medicine. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company’s global network
of capabilities enables its 37,000 employees across 58 markets to push the boundaries of scientific innovation and deliver quality medicines
to help improve health outcomes of millions of patients every day. To learn more about how Teva is all in for better health, visit www.tevapharm.com.
http://www.tevapharm.com.
Some amounts in this press release may not add up due to rounding. All percentages have been calculated using unrounded amounts.
Non-GAAP Financial Measures
This press release contains certain financial information that differs from what is reported under accounting principles generally
accepted in the United States ("GAAP"). These non-GAAP financial measures, including, but not limited to, non-GAAP operating income, non-GAAP
operating margin, non-GAAP gross profit, non-GAAP gross profit margin, Adjusted EBITDA, free cash flow, non-GAAP tax rate, non-GAAP net
income (loss) attributable to Teva and non-GAAP diluted EPS, are presented in order to facilitate investors' understanding of our business.
We utilize certain non-GAAP financial measures to evaluate performance, in conjunction with other performance metrics. The following are
examples of how we utilize the non-GAAP measures: our management and board of directors use the non-GAAP measures to evaluate our operational
performance, to compare against work plans and budgets, and ultimately to evaluate the performance of management; our annual budgets are
prepared on a non-GAAP basis; and senior management’s annual compensation is derived, in part, using these non-GAAP measures. See
the attached tables for a reconciliation of the GAAP results to the adjusted non-GAAP measures. Investors should consider non-GAAP financial
measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.
We are not providing forward looking guidance for GAAP reported financial measures or a quantitative reconciliation of forward-looking
non-GAAP financial measures to the most directly comparable GAAP measure because we are unable to predict with reasonable certainty the
ultimate outcome of certain significant items including, but not limited to, the amortization of purchased intangible assets, legal settlements
and loss contingencies, impairment of long-lived assets and goodwill impairment, without unreasonable effort. These items are uncertain,
depend on various factors, and could be material to our results computed in accordance with GAAP.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties,
both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or
implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,”
“expect,” “anticipate,” “estimate,” “target,” “may,” “project,”
“guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and
expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute
to such differences include risks relating to:
- our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; concentration
of our customer base and commercial alliances among our customers; delays in launches of new generic products; our ability to develop
and commercialize biopharmaceutical products; competition for our innovative medicines; our ability to achieve expected results from investments
in our product pipeline; our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute
our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative
medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generics
medicines; and the effectiveness of our patents and other measures to protect our intellectual property rights, including any potential
challenges to our Orange Book patent listings in the U.S.;
- our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make
new investments, may result in a future downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or
on terms that are favorable to us;
- our business and operations in general, including: the impact of global economic conditions and other macroeconomic developments and
the governmental and societal responses thereto; the widespread outbreak of an illness or any other communicable disease, or any other
public health crisis; effectiveness of our optimization efforts; our ability to attract, hire, integrate and retain highly skilled personnel;
interruptions in our supply chain or problems with internal or third party manufacturing; disruptions of information technology systems;
breaches of our data security; challenges associated with conducting business globally, including political or economic instability, major
hostilities or terrorism, such as the ongoing conflict between Russia and Ukraine and the state of war declared in Israel; costs and delays
resulting from the extensive pharmaceutical regulation to which we are subject; our ability to successfully bid for suitable acquisition
targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we
sell assets or business units and close or divest plants and facilities, as well as our ability to successfully and cost-effectively consummate
such sales and divestitures, including our planned divestiture of our API business;
- compliance, regulatory and litigation matters, including: failure to comply with complex legal and regulatory environments; the effects
of governmental and civil proceedings and litigation which we are, or in the future become, party to; the effects of reforms in healthcare
regulation and reductions in pharmaceutical pricing, reimbursement and coverage; increased legal and regulatory action in connection with
public concern over the abuse of opioid medications; our ability to timely make payments required under our nationwide opioids settlement
agreement and provide our generic version of Narcan® (naloxone hydrochloride nasal spray) in the amounts and at the times
required under the terms of such agreement; scrutiny from competition and pricing authorities around the world, including our ability
to comply with and operate under our deferred prosecution agreement (DPA) with the U.S. Department of Justice; potential liability for
intellectual property right infringement; product liability claims; failure to comply with complex Medicare, Medicaid and other governmental
programs reporting and payment obligations; compliance with anti-corruption, sanctions and trade control laws; environmental risks; and
the impact of sustainability issues;
- the impact of the state of war declared in Israel and the military activity in the region, including the risk of disruptions to our
operations and facilities, such as our manufacturing and R&D facilities, located in Israel, the impact of our employees who are military
reservists being called to active military duty, and the impact of the war on the economic, social and political stability of Israel;
- other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential
impairments of our long-lived assets; the impact of geopolitical conflicts including the state of war declared in Israel and the conflict
between Russia and Ukraine; potential significant increases in tax liabilities; the effect on our overall effective tax rate of the termination
or expiration of governmental programs or tax benefits, or of a change in our business and our ability to remediate an existing material
weakness in our internal control over financial reporting;
and other factors discussed in this press release,
in our Quarterly Report on Form 10-Q for the second quarter of 2024 and in our Annual Report on Form 10-K for the year ended December
31, 2023, including in the section captioned "Risk Factors.” Forward-looking statements speak only as of the date on which they
are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether
as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
| Consolidated Statements of Income
|
| (U.S. dollars in millions, except share
and per share data) |
| (Unaudited) |
| |
|
|
|
|
|
|
|
|
|
| |
|
Three months ended |
|
|
Six months ended |
| |
|
June
30, |
|
|
June
30, |
| |
|
2024 |
|
2023 |
|
|
2024 |
|
2023 |
| Net revenues |
|
4,164 |
|
3,878 |
|
|
7,983 |
|
7,539 |
| Cost of sales |
|
2,140 |
|
2,082 |
|
|
4,188 |
|
4,161 |
| Gross profit |
|
2,024 |
|
1,796 |
|
|
3,795 |
|
3,378 |
| Research and development expenses |
|
269 |
|
240 |
|
|
511 |
|
473 |
| Selling and marketing expenses |
|
656 |
|
603 |
|
|
1,265 |
|
1,149 |
| General and administrative expenses |
|
283 |
|
307 |
|
|
561 |
|
602 |
| Intangible assets impairments |
|
61 |
|
63 |
|
|
141 |
|
241 |
| Goodwill impairment |
|
400 |
|
700 |
|
|
400 |
|
700 |
| Other asset impairments, restructuring and other items |
|
280 |
|
108 |
|
|
954 |
|
218 |
| Legal settlements and loss contingencies |
|
83 |
|
462 |
|
|
188 |
|
695 |
| Other income |
|
(2) |
|
(33) |
|
|
(1) |
|
(34) |
| Operating income (loss) |
|
(5) |
|
(654) |
|
|
(223) |
|
(667) |
| Financial expenses, net |
|
241 |
|
268 |
|
|
491 |
|
528 |
| Income (loss) before income taxes |
|
(246) |
|
(923) |
|
|
(713) |
|
(1,195) |
| Income taxes (benefit) |
|
630 |
|
(16) |
|
|
578 |
|
(35) |
| Share in (profits) losses of associated companies, net |
|
(2) |
|
(1) |
|
|
2 |
|
(1) |
| Net income (loss) |
|
(874) |
|
(906) |
|
|
(1,294) |
|
(1,159) |
| Net income (loss) attributable to non-controlling interests |
|
(29) |
|
(35) |
|
|
(309) |
|
(68) |
| Net income (loss) attributable to Teva |
|
(846) |
|
(872) |
|
|
(985) |
|
(1,091) |
| |
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
| Earnings
(loss) per share attributable to Teva: |
Basic ($) |
(0.75) |
|
(0.78) |
|
|
(0.87) |
|
(0.98) |
| |
Diluted ($) |
(0.75) |
|
(0.78) |
|
|
(0.87) |
|
(0.98) |
| Weighted average number of
shares (in millions): |
Basic |
1,133 |
|
1,120 |
|
|
1,128 |
|
1,118 |
| |
Diluted |
1,133 |
|
1,120 |
|
|
1,128 |
|
1,118 |
| |
|
|
|
|
|
|
|
|
|
| Non-GAAP
net income attributable to Teva for diluted earnings per share:* |
|
697 |
|
629 |
|
|
1,245 |
|
1,085 |
| |
|
|
|
|
|
|
|
|
|
| Non-GAAP earnings per share
attributable to Teva:* |
Diluted ($) |
0.61 |
|
0.56 |
|
|
1.09 |
|
0.96 |
| |
|
|
|
|
|
|
|
|
|
| Non-GAAP average number of
shares (in millions): |
Diluted |
1,151 |
|
1,129 |
|
|
1,146 |
|
1,127 |
| |
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
| Amounts may not add up due to rounding. |
| |
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
| * See reconciliation attached. |
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
| CONSOLIDATED BALANCE SHEETS |
| (U.S. dollars in millions, except for share
data) |
| (Unaudited) |
| |
|
|
|
|
|
|
| |
|
June 30, |
|
December 31, |
| |
|
2024 |
|
2023 |
| ASSETS |
|
|
|
|
|
|
| Current assets: |
|
|
|
|
|
|
| Cash and cash equivalents |
|
$ |
2,258 |
|
$ |
3,226 |
| Accounts receivables, net of allowance for credit
losses of $95 million as of June 30, 2024 and as of December 31, 2023. |
|
|
3,766 |
|
|
3,408 |
| Inventories |
|
|
3,927 |
|
|
4,021 |
| Prepaid expenses |
|
|
1,096 |
|
|
1,255 |
| Other current assets |
|
|
517 |
|
|
504 |
| Assets held for sale |
|
|
69 |
|
|
70 |
| Total current assets |
|
|
11,632 |
|
|
12,485 |
| Deferred income taxes |
|
|
2,000 |
|
|
1,812 |
| Other non-current assets |
|
|
434 |
|
|
470 |
| Property, plant and equipment, net |
|
|
5,573 |
|
|
5,750 |
| Operating lease right-of-use assets,
net |
|
|
358 |
|
|
397 |
| Identifiable intangible assets, net |
|
|
4,853 |
|
|
5,387 |
| Goodwill |
|
|
16,488 |
|
|
17,177 |
| Total assets |
|
$ |
41,338 |
|
$ |
43,479 |
| |
|
|
|
|
|
|
| LIABILITIES AND EQUITY |
|
|
|
|
|
|
| Current liabilities: |
|
|
|
|
|
|
| Short-term debt |
|
$ |
2,094 |
|
$ |
1,672 |
| Sales reserves and allowances |
|
|
3,700 |
|
|
3,535 |
| Accounts payables |
|
|
2,366 |
|
|
2,602 |
| Employee-related obligations |
|
|
492 |
|
|
611 |
| Accrued expenses |
|
|
2,840 |
|
|
2,771 |
| Other current liabilities |
|
|
1,191 |
|
|
1,044 |
| Liabilities held for sale |
|
|
356 |
|
|
13 |
| Total current liabilities |
|
|
13,037 |
|
|
12,247 |
| |
|
|
|
|
|
|
| Long-term liabilities: |
|
|
|
|
|
|
| Deferred income taxes |
|
|
553 |
|
|
606 |
| Other taxes and long-term liabilities |
|
|
4,356 |
|
|
4,019 |
| Senior notes and loans |
|
|
16,547 |
|
|
18,161 |
| Operating lease liabilities |
|
|
281 |
|
|
320 |
| Total long-term liabilities |
|
|
21,737 |
|
|
23,106 |
| Equity: |
|
|
|
|
|
|
| Teva shareholders’ equity: |
|
|
6,359 |
|
|
7,506 |
| Non-controlling interests |
|
|
204 |
|
|
620 |
| Total equity |
|
|
6,563 |
|
|
8,126 |
| Total liabilities and equity |
|
$ |
41,338 |
|
$ |
43,479 |
| |
|
|
|
|
|
|
| Amounts may not add up due to rounding. |
| |
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
|
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
(U.S. dollars in millions)
|
(Unaudited)
|
| |
|
|
|
|
|
|
|
|
|
|
| |
|
Three months ended |
|
|
Six months ended |
| |
|
June
30, |
|
|
June
30, |
| |
|
2024
|
2023 |
|
2024 |
2023 |
| Operating activities: |
|
|
|
|
|
|
|
|
|
|
| Net income (loss) |
$ |
(874 |
) |
(906 |
) |
$ |
(1,294 |
) |
(1,159 |
) |
| Adjustments to reconcile net income (loss) to net cash provided
by operations: |
|
|
|
|
|
|
|
|
|
|
| Depreciation and amortization |
|
259 |
|
300 |
|
|
531 |
|
604 |
|
| Impairment of goodwill |
|
400 |
|
700 |
|
|
400 |
|
700 |
|
| Impairment of long-lived assets and assets held for sale |
|
130 |
|
74 |
|
|
809 |
|
262 |
|
| Net change in operating assets and liabilities |
|
(10 |
) |
212 |
|
|
(507 |
) |
(137 |
) |
| Deferred income taxes – net and uncertain tax positions |
|
(424 |
) |
(44 |
) |
|
(613 |
) |
(150 |
) |
| Stock-based compensation |
|
32 |
|
30 |
|
|
60 |
|
62 |
|
| Other items * |
|
592 |
|
(12 |
) |
|
594 |
|
23 |
|
| Net loss (gain) from investments and from sale of long lived
assets |
|
(1 |
) |
(30 |
) |
|
(1 |
) |
(26 |
) |
| Net cash provided by (used in) operating activities |
|
103 |
|
324 |
|
|
(21 |
) |
179 |
|
| |
|
|
|
|
|
|
|
|
|
|
| Investing activities: |
|
|
|
|
|
|
|
|
|
|
| Beneficial interest collected in exchange for securitized
trade receivables |
|
317 |
|
371 |
|
|
612 |
|
694 |
|
| Purchases of property, plant and equipment and intangible
assets |
|
(97 |
) |
(119 |
) |
|
(221 |
) |
(258 |
) |
| Proceeds from sale of business and long lived assets |
|
1 |
|
56 |
|
|
1 |
|
58 |
|
| Acquisition of businesses, net of cash acquired |
|
- |
|
- |
|
|
(15 |
) |
- |
|
| Purchases of investments and other assets . |
|
(43 |
) |
(2 |
) |
|
(55 |
) |
(6 |
) |
| Other investing activities |
|
- |
|
(4 |
) |
|
- |
|
(5 |
) |
| Net cash provided by (used in) investing activities |
|
178 |
|
302 |
|
|
322 |
|
483 |
|
| |
|
|
|
|
|
|
|
|
|
|
| Financing activities: |
|
|
|
|
|
|
|
|
|
|
| Purchase of shares from non-controlling interests |
|
- |
|
- |
|
|
(64 |
) |
- |
|
| Dividends paid to non-controlling interests |
|
- |
|
- |
|
|
(78 |
) |
- |
|
| Repayment of senior notes and loans and other long term liabilities |
|
(956 |
) |
- |
|
|
(956 |
) |
(3,152 |
) |
| Proceeds from senior notes, net of issuance costs |
|
- |
|
- |
|
|
- |
|
2,451 |
|
| Other financing activities |
|
(10 |
) |
(55 |
) |
|
(19 |
) |
(60 |
) |
| Net cash provided by (used in) financing activities |
|
(966 |
) |
(55 |
) |
|
(1,117 |
) |
(761 |
) |
| |
|
|
|
|
|
|
|
|
|
|
| Translation adjustment on cash and cash equivalents |
|
(49 |
) |
(77 |
) |
|
(153 |
) |
(65 |
) |
| |
|
|
|
|
|
|
|
|
|
|
| Net change in cash, cash equivalents and restricted
cash |
|
(733 |
) |
494 |
|
|
(969 |
) |
(164 |
) |
| Balance of cash, cash equivalents and restricted
cash at beginning of period |
|
2,991 |
|
2,176 |
|
|
3,227 |
|
2,834 |
|
| |
|
|
|
|
|
|
|
|
|
|
| Balance of cash, cash equivalents and restricted
cash at end of period |
$ |
2,258 |
|
2,670 |
|
$ |
2,258 |
|
2,670 |
|
| |
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
| Cash and cash equivalents |
|
2,258 |
|
2,669 |
|
|
2,258 |
|
2,669 |
|
| Restricted cash included in other current assets |
|
— |
|
1 |
|
|
— |
|
1 |
|
| Total cash, cash equivalents and restricted cash
shown in the statement of cash flows |
|
2,258 |
|
2,670 |
|
|
2,258 |
|
2,670 |
|
| |
|
|
|
|
|
|
|
|
|
|
| Non-cash financing and investing activities: |
|
|
|
|
|
|
|
|
|
|
| Beneficial interest obtained in exchange for securitized
accounts receivables |
$ |
320 |
|
380 |
|
$ |
632 |
|
714 |
|
| |
|
|
|
|
|
|
|
|
|
|
| * Adjustment in the three months period ended
June 30, 2024 mainly relate to an agreement with the Israeli Tax Authorities. |
| |
|
|
|
|
|
|
|
|
|
|
Amounts may not add up due to rounding
|
The accompanying notes are an integral
part of the financial statements.
|
| |
|
|
|
|
|
|
|
|
|
|
| Reconciliation of gross profit to Non-GAAP
gross profit |
| (Unaudited) |
| |
|
|
Three months ended |
|
|
Six months ended |
| |
|
|
June 30, |
|
|
June 30, |
| ($ in millions) |
|
|
2024 |
2023 |
|
|
2024 |
2023 |
| Gross profit |
|
$ |
2,024 |
1,796 |
|
$ |
3,795 |
3,378 |
| Gross profit margin |
|
|
48.6% |
46.3% |
|
|
47.5% |
44.8% |
| Increase (decrease) for excluded items: |
|
|
|
|
|
|
|
| |
Amortization of purchased intangible assets |
|
136 |
145 |
|
|
273 |
290 |
| |
Equity compensation |
|
7 |
5 |
|
|
13 |
10 |
| |
Accelerated depreciation |
|
0 |
24 |
|
|
7 |
49 |
| |
Other non-GAAP items (1) |
|
37 |
52 |
|
|
80 |
91 |
| Non-GAAP gross profit |
$ |
2,205 |
2,023 |
|
$ |
4,168 |
3,819 |
| Non-GAAP gross profit margin (2) |
|
52.9% |
52.2% |
|
|
52.2% |
50.7% |
| |
|
|
|
|
|
|
|
| (1) Other non-GAAP items include other exceptional
items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial
results, primarily related to the rationalization of our plants, certain inventory write-offs and other unusual events. |
| (2) Non-GAAP gross profit margin is non-GAAP
gross profit as a percentage of revenue. |
| |
|
|
|
|
|
|
|
|
| Reconciliation of operating income
(loss) to Non-GAAP operating income (loss) |
| (Unaudited) |
| |
|
|
Three months ended |
|
|
Six months ended |
| |
|
|
June 30, |
|
|
June 30, |
| ($ in millions) |
|
2024 |
2023 |
|
|
2024 |
2023 |
| Operating income (loss)(1) |
($) |
(5) |
(654) |
|
($) |
(223) |
(667) |
| Operating margin |
|
(0.1%) |
(16.9%) |
|
|
(2.8%) |
(8.8%) |
| Increase (decrease) for excluded items: |
|
|
|
|
|
|
|
| |
Amortization of
purchased intangible assets |
|
146 |
162 |
|
|
298 |
326 |
| |
Legal settlements and loss contingencies(2) |
|
83 |
462 |
|
|
188 |
695 |
| |
Goodwill impairment(3) |
|
400 |
700 |
|
|
400 |
700 |
| |
Impairment of long-lived assets(4) |
|
130 |
74 |
|
|
809 |
262 |
| |
Restructuring costs |
|
18 |
10 |
|
|
31 |
66 |
| |
Equity compensation |
|
32 |
30 |
|
|
60 |
62 |
| |
Contingent consideration(1)(5) |
|
192 |
78 |
|
|
271 |
113 |
| |
Accelerated depreciation |
|
0 |
24 |
|
|
7 |
49 |
| |
Other non-GAAP items(6) |
|
59 |
125 |
|
|
106 |
189 |
| Non-GAAP operating income (loss) |
($) |
1,056 |
1,011 |
|
($) |
1,948 |
1,796 |
| Non-GAAP operating margin(3) |
($) |
25.3% |
26.1% |
|
($) |
24.4% |
23.8% |
| |
|
|
|
|
|
|
|
|
| (1) The data presented for the prior period have
been revised to reflect a revision in the presentation of these items in the consolidated financial statements. For additional information
see note 1b to our consolidated financial statements included in our 2023 Annual Report on Form 10-K. |
| (2) Adjustments for legal settlements and loss contingencies
in the second quarter of 2023 were mainly related to a provision of $200 million in connection with the U.S. DOJ criminal antitrust charges
on the marketing and pricing of certain Teva USA generic products and an update to the estimated settlement provision of $170 million
related to some of the remaining opioid cases including an agreement in principle on private hospital cases. Adjustments for legal settlements
and loss contingencies in the first six months of 2023 were mainly related to an update to the estimated settlement provision of $206
million related to the remaining opioid cases, the provision of $210 million relating to the U.S. DOJ criminal antitrust charges on the
marketing and pricing of certain Teva USA generic products, an update to the estimated provision of $102 million related to the DOJ patient
assistance program litigation, and the provision of $100 million related to the settlement of the reverse-payment antitrust litigation
over certain HIV medicines. |
| (3) A goodwill impairment charge of $400 million
related to our Teva's API reporting unit was recognized in the three and six months ended June 2024, compared to a goodwill impairment
charge of $700 million related to our International Markets reporting unit recognized in the three and six months ended June 2023. |
| (4) Adjustments for impairment of long-lived assets,
for the six months ended June 30, 2024, primarily consisted of $644 million related to the classification of our business venture in Japan
as held for sale. |
| (5) Adjustments for contingent consideration primarily
related to a change in the estimated future royalty payments to Allergan in connection with lenalidomide capsules (the generic version
of Revlimid®), of $174 million and $238 million, respectively for the three and six months ended June 30, 2024, and of $64 million
and $88 million, respectively for the three and six months ended June 30, 2023. |
| (6) Other non-GAAP items include other exceptional
items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial
results, primarily related to the rationalization of our plants, certain inventory write-offs, material litigation fees and other unusual
events. |
| |
| Reconciliation of net income (loss)
attributable to Teva |
| to Non-GAAP net income (loss) attributable
to Teva |
| (Unaudited) |
| |
|
|
|
|
|
|
|
|
| |
|
|
Three months ended |
|
|
Six months ended |
| |
|
|
June 30, |
|
|
June 30, |
| ($ in millions except per share amounts) |
|
2024 |
2023 |
|
|
2024 |
2023 |
| Net income (Loss) attributable to Teva(1) |
($) |
(846) |
(872) |
|
($) |
(985) |
(1,091) |
| Increase (decrease) for excluded items: |
|
|
|
|
|
|
|
| |
Amortization of purchased intangible assets |
|
146 |
162 |
|
|
298 |
326 |
| |
Legal settlements and loss contingencies(2) |
|
83 |
462 |
|
|
188 |
695 |
| |
Goodwill impairment(3) |
|
400 |
700 |
|
|
400 |
700 |
| |
Impairment of long-lived assets(4) |
|
130 |
74 |
|
|
809 |
262 |
| |
Restructuring costs |
|
18 |
10 |
|
|
31 |
66 |
| |
Equity compensation |
|
32 |
30 |
|
|
60 |
62 |
| |
Contingent consideration(1)(5) |
|
192 |
78 |
|
|
271 |
113 |
| |
Accelerated depreciation |
|
- |
24 |
|
|
7 |
49 |
| |
Financial expenses |
|
12 |
16 |
|
|
24 |
39 |
| |
Items attributable to non-controlling interests(4) |
|
(33) |
(49) |
|
|
(317) |
(90) |
| |
Other non-GAAP items(6) |
|
59 |
125 |
|
|
106 |
189 |
| |
Corresponding tax effects and unusual tax items(7) |
|
503 |
(131) |
|
|
353 |
(235) |
| Non-GAAP net income attributable to Teva |
($) |
697 |
629 |
|
($) |
1,245 |
1,085 |
| Non-GAAP tax rate(8) |
|
15.4% |
15.2% |
|
|
15.2% |
15.3% |
| GAAP diluted earnings (loss) per share attributable
to Teva |
($) |
(0.75) |
(0.78) |
|
($) |
(0.87) |
(0.98) |
| EPS difference(9) |
|
1.35 |
1.34 |
|
|
1.96 |
1.94 |
| Non-GAAP diluted EPS attributable to Teva(9) |
($) |
0.61 |
0.56 |
|
($) |
1.09 |
0.96 |
| Non-GAAP average number of shares (in millions)(9) |
|
1,151 |
1,129 |
|
|
1,146 |
1,127 |
| |
|
|
|
|
|
|
|
|
| (1) |
The data presented for the prior period have been
revised to reflect a revision in the presentation of these items in the consolidated financial statements. For additional information
see note 1b to our consolidated financial statements included in our 2023 Annual Report on Form 10-K. |
| (2) |
Adjustments for legal settlements and loss contingencies
in the second quarter of 2023 were mainly related to a provision of $200 million in connection with the U.S. DOJ criminal antitrust charges
on the marketing and pricing of certain Teva USA generic products and an update to the estimated settlement provision of $170 million
related to some of the remaining opioid cases including an agreement in principle on private hospital cases. Adjustments for legal settlements
and loss contingencies in the first six months of 2023 were mainly related to an update to the estimated settlement provision of $206
million related to the remaining opioid cases, the provision of $210 million relating to the U.S. DOJ criminal antitrust charges on the
marketing and pricing of certain Teva USA generic products, an update to the estimated provision of $102 million related to the DOJ patient
assistance program litigation, and the provision of $100 million related to the settlement of the reverse-payment antitrust litigation
over certain HIV medicines. |
| (3) |
A goodwill impairment charge of $400 million related
to our Teva's API reporting unit was recognized in the three and six months ended June 30, 2024, compared to a goodwill impairment charge
of $700 million related to our International Markets reporting unit recognized in the three and six months ended June 2023. |
| (4) |
Adjustments for impairment of long-lived assets
and items attributable to non-controlling interests for the six months ended June 30, 2024, primarily consisted of $644 million and $317
million, respectively, related to the classification of our business venture in Japan as held for sale. |
| (5) |
Adjustments for contingent consideration primarily
related to a change in the estimated future royalty payments to Allergan in connection with lenalidomide capsules (the generic version
of Revlimid®), of $174 million and $238 million, respectively for the three and six months ended June 30, 2024, and of $64 million
and $88 million, respectively for the three and six months ended June 30, 2023. |
| (6) |
Other non-GAAP items include other exceptional items
that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results,
primarily related to the rationalization of our plants, certain inventory write-offs, material litigation fees and other unusual events. |
| (7) |
Adjustments for corresponding tax effects and unusual
tax items for the three months ended June 30,2024 mainly related to the settlement agreement with the ITA to settle certain litigation
with respect to taxes payable for the Company’s taxable years 2008 through 2020, in an amount of $495 million. |
| (8) |
Non-GAAP tax rate is tax expenses (benefit) excluding
the impact of non-GAAP tax adjustments presented above as a percentage of income (loss) before income taxes excluding the impact of non-GAAP
adjustments presented above. GAAP tax rate for the three and six months ended June 30, 2024 was 256% and 81% respectively and for the
three and six months ended June 30, 2023 was 2% and 3% respectively. |
| (9) |
EPS difference and diluted non-GAAP EPS are calculated
by dividing our non-GAAP net income attributable to Teva by our non-GAAP diluted weighted average number of shares. |
| |
|
|
|
|
|
|
|
|
Reconciliation of net income (loss)
to adjusted EBITDA
|
| (Unaudited) |
| |
|
|
|
|
|
|
|
|
|
| |
|
|
Three months ended |
|
Six months ended |
| |
|
|
June 30, |
|
June 30, |
| ($ in millions) |
|
2024 |
|
2023 |
|
|
2024 |
|
2023 |
|
| Net income (loss)(1)
|
$ |
(874 |
) |
(906 |
) |
$ |
(1,294 |
) |
(1,159 |
) |
| Increase (decrease) for excluded items: |
|
|
|
|
|
|
|
|
|
|
| |
Financial expenses |
|
241 |
|
268 |
|
|
491 |
|
528 |
|
| |
Income taxes |
|
630 |
|
(16 |
) |
|
578 |
|
(35 |
) |
| |
Share in profits (losses) of associated companies –net |
|
(2 |
) |
(1 |
) |
|
2 |
|
(1 |
) |
| |
Depreciation |
|
113 |
|
138 |
|
|
233 |
|
278 |
|
| |
Amortization |
|
146 |
|
162 |
|
|
298 |
|
326 |
|
| EBITDA |
|
254 |
|
(355 |
) |
|
308 |
|
(63 |
) |
| |
Legal settlements and loss contingencies(2) |
83 |
|
462 |
|
|
188 |
|
695 |
|
| |
Goodwill impairment(3) |
|
400 |
|
700 |
|
|
400 |
|
700 |
|
| |
Impairment of long lived assets(4) |
130 |
|
74 |
|
|
809 |
|
262 |
|
| |
Restructuring costs |
|
18 |
|
10 |
|
|
31 |
|
66 |
|
| |
Equity compensation |
|
32 |
|
30 |
|
|
60 |
|
62 |
|
| |
Contingent consideration(5) |
|
192 |
|
78 |
|
|
271 |
|
113 |
|
| |
Other non-GAAP items (6) |
|
59 |
|
125 |
|
|
106 |
|
189 |
|
| Adjusted EBITDA |
$ |
1,168 |
|
1,125 |
|
$ |
2,173 |
|
2,024 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
| |
(1) The data presented for the prior period
have been revised to reflect a revision in the presentation of these items in the consolidated financial statements. For additional information
see note 1b to our consolidated financial statements included in our 2023 Annual Report on Form 10-K. |
| |
(2) Adjustments for legal settlements and loss
contingencies in the second quarter of 2023 were mainly related to a provision of $200 million in connection with the U.S. DOJ criminal
antitrust charges on the marketing and pricing of certain Teva USA generic products and an update to the estimated settlement provision
of $170 million related to some of the remaining opioid cases including an agreement in principle on private hospital cases. Adjustments
for legal settlements and loss contingencies in the first six months of 2023 were mainly related to an update to the estimated settlement
provision of $206 million related to the remaining opioid cases, the provision of $210 million relating to the U.S. DOJ criminal antitrust
charges on the marketing and pricing of certain Teva USA generic products, an update to the estimated provision of $102 million related
to the DOJ patient assistance program litigation, and the provision of $100 million related to the settlement of the reverse-payment antitrust
litigation over certain HIV medicines. |
| |
(3) A goodwill impairment charge of $400 million
related to our Teva's API reporting unit was recognized in the three and six months ended June 2024, compared to a goodwill impairment
charge of $700 million related to our International Markets reporting unit recognized in the three and six months ended June 2023. |
| |
(4) Adjustments for impairment of long-lived
assets, for the six months ended June 30, 2024, primarily consisted of $644 million related to the classification of our business venture
in Japan as held for sale |
| |
(5) Adjustments for contingent consideration
primarily related to a change in the estimated future royalty payments to Allergan in connection with lenalidomide capsules (the generic
version of Revlimid®), of $174 million and $238 million, respectively for the three and six months ended June 30, 2024, and of $64
million and $88 million, respectively for the three and six months ended June 30, 2023. |
| |
(6) Other non-GAAP items include other exceptional
items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial
results, primarily related to the rationalization of our plants, certain inventory write-offs, material litigation fees and other unusual
events. |
| |
|
| Segment Information |
| (Unaudited) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
United
States |
|
Europe |
|
International
Markets |
| |
Three
months ended June 30, |
|
Three
months ended June 30, |
|
Three
months ended June 30, |
| |
2024 |
|
2023 |
|
2024 |
|
2023 |
|
2024 |
|
2023 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
(U.S. $ in millions) |
|
(U.S. $ in millions) |
|
(U.S. $ in millions) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Revenues |
$ |
2,110 |
|
|
$ |
1,892 |
|
|
$ |
1,213 |
|
|
$ |
1,163 |
|
|
$ |
593 |
|
|
$ |
578 |
|
| Gross profit |
|
1,167 |
|
|
|
1,017 |
|
|
|
677 |
|
|
|
640 |
|
|
|
286 |
|
|
|
283 |
|
| R&D expenses |
|
170 |
|
|
|
156 |
|
|
|
62 |
|
|
|
53 |
|
|
|
30 |
|
|
|
23 |
|
| S&M expenses |
|
270 |
|
|
|
250 |
|
|
|
209 |
|
|
|
194 |
|
|
|
145 |
|
|
|
125 |
|
| G&A expenses |
|
100 |
|
|
|
101 |
|
|
|
64 |
|
|
|
61 |
|
|
|
38 |
|
|
|
34 |
|
| Other income |
|
(1 |
) |
|
|
(1 |
) |
|
|
§ |
|
|
|
(1 |
) |
|
|
§ |
|
|
|
(31 |
) |
| Segment profit |
$ |
629 |
|
|
$ |
511 |
|
|
$ |
342 |
|
|
$ |
334 |
|
|
$ |
73 |
|
|
$ |
132 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| § Represents an amount less than $0.5 million. |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Segment Information |
| (Unaudited) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
United
States |
|
Europe |
|
International
Markets |
| |
Six
months ended June 30, |
|
Six
months ended June 30, |
|
Six
months ended June 30, |
| |
2024 |
|
2023 |
|
2024 |
|
2023 |
|
2024 |
|
2023 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
(U.S. $ in millions) |
|
(U.S. $ in millions) |
|
(U.S. $ in millions) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Revenues |
$ |
3,835 |
|
|
$ |
3,569 |
|
|
$ |
2,485 |
|
|
$ |
2,347 |
|
|
$ |
1,190 |
|
|
$ |
1,159 |
|
| Gross profit |
|
2,025 |
|
|
|
1,806 |
|
|
|
1,415 |
|
|
|
1,294 |
|
|
|
583 |
|
|
|
568 |
|
| R&D expenses |
|
324 |
|
|
|
305 |
|
|
|
118 |
|
|
|
106 |
|
|
|
58 |
|
|
|
51 |
|
| S&M expenses |
|
530 |
|
|
|
457 |
|
|
|
403 |
|
|
|
381 |
|
|
|
263 |
|
|
|
238 |
|
| G&A expenses |
|
193 |
|
|
|
196 |
|
|
|
130 |
|
|
|
130 |
|
|
|
73 |
|
|
|
72 |
|
| Other income |
|
(1 |
) |
|
|
(1 |
) |
|
|
§ |
|
|
|
(1 |
) |
|
|
(1 |
) |
|
|
(33 |
) |
| Segment profit |
$ |
979 |
|
|
$ |
850 |
|
|
$ |
764 |
|
|
$ |
679 |
|
|
$ |
190 |
|
|
$ |
240 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
§ Represents an amount less than $0.5 million.
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Reconciliation of our segment profit |
| to consolidated income before income
taxes |
| Unaudited |
| |
|
Three months ended |
| |
|
June
30, |
| |
|
2024 |
|
2023 |
| |
|
|
|
|
|
|
|
|
| |
|
(U.S.$ in millions) |
| |
|
|
|
|
|
|
|
|
| United States profit |
|
$ |
629 |
|
|
$ |
511 |
|
| Europe profit |
|
|
342 |
|
|
|
334 |
|
| International Markets profit |
|
|
73 |
|
|
|
132 |
|
| Total reportable segment profit |
|
|
1,043 |
|
|
|
977 |
|
| Profit of other activities |
|
|
12 |
|
|
|
33 |
|
| |
|
|
1,056 |
|
|
|
1,011 |
|
| Amounts not allocated to segments: |
|
|
|
|
|
|
|
|
| Amortization |
|
|
146 |
|
|
|
162 |
|
| Other asset impairments, restructuring
and other items* |
|
|
280 |
|
|
|
108 |
|
| Goodwill impairment |
|
|
400 |
|
|
|
700 |
|
| Intangible asset impairments |
|
|
61 |
|
|
|
63 |
|
| Legal settlements and loss contingencies |
|
|
83 |
|
|
|
462 |
|
| Other unallocated amounts |
|
|
91 |
|
|
|
170 |
|
| Consolidated operating income (loss) |
|
|
(5 |
) |
|
|
(654 |
) |
| Financial expenses - net |
|
|
241 |
|
|
|
268 |
|
| Consolidated income (loss) before income taxes* |
|
$ |
(246 |
) |
|
$ |
(923 |
) |
| |
|
|
|
|
|
|
|
|
| *The data presented for the prior period have
been revised to reflect a revision in the presentation of these items in the consolidated financial statements. For additional information
see note 1b to our consolidated financial statements included in our 2023 Annual Report on Form 10-K. |
| |
|
|
|
|
|
|
|
|
| Reconciliation of our segment profit |
| to consolidated income before income
taxes |
| Unaudited |
| |
|
Six months ended |
| |
|
June
30, |
| |
|
2024 |
|
2023 |
| |
|
|
|
|
|
|
|
|
| |
|
(U.S.$ in millions) |
| |
|
|
|
|
|
|
|
|
| United States profit |
|
$ |
979 |
|
|
$ |
850 |
|
| Europe profit |
|
|
764 |
|
|
|
679 |
|
| International Markets profit |
|
|
190 |
|
|
|
240 |
|
| Total reportable segment profit |
|
|
1,933 |
|
|
|
1,769 |
|
| Profit of other activities |
|
|
15 |
|
|
|
27 |
|
| Total segment profit |
|
|
1,948 |
|
|
|
1,796 |
|
| Amounts not allocated to segments: |
|
|
|
|
|
|
|
|
| Amortization |
|
|
298 |
|
|
|
326 |
|
| Other asset impairments, restructuring
and other items* |
|
|
954 |
|
|
|
218 |
|
| Goodwill impairment |
|
|
400 |
|
|
|
700 |
|
| Intangible asset impairments |
|
|
141 |
|
|
|
241 |
|
| Legal settlements and loss contingencies |
|
|
188 |
|
|
|
695 |
|
| Other unallocated amounts |
|
|
190 |
|
|
|
282 |
|
| Consolidated operating income (loss) |
|
|
(223 |
) |
|
|
(667 |
) |
| Financial expenses - net |
|
|
491 |
|
|
|
528 |
|
| Consolidated income (loss) before income taxes* |
|
$ |
(713 |
) |
|
$ |
(1,195 |
) |
| |
|
|
|
|
|
|
|
|
| The data presented for the prior period have
been revised to reflect a revision in the presentation of these items in the consolidated financial statements. For additional information
see note 1b to our consolidated financial statements included in our 2023 Annual Report on Form 10-K. |
| |
| Segment revenues by major products
and activities |
| (Unaudited) |
| |
|
|
|
|
|
|
|
|
| |
|
Three
months ended |
|
|
| |
|
June
30, |
|
Percentage Change |
| |
|
2024 |
|
2023 |
|
2023-2024 |
| |
|
(U.S.$
in millions) |
|
|
| United States segment |
|
|
|
|
|
|
|
|
| Generic products |
|
$ |
1,023 |
|
$ |
884 |
|
16% |
| AJOVY |
|
|
42 |
|
|
52 |
|
(20%) |
| AUSTEDO |
|
|
407 |
|
|
308 |
|
32% |
| BENDEKA/TREANDA |
|
|
41 |
|
|
67 |
|
(39%) |
| COPAXONE |
|
|
81 |
|
|
56 |
|
44% |
| Anda |
|
|
373 |
|
|
392 |
|
(5%) |
| Other |
|
|
144 |
|
|
131 |
|
9% |
| Total |
|
|
2,110 |
|
|
1,892 |
|
12% |
| |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
| |
|
Three
months ended |
|
|
| |
|
June
30, |
|
Percentage Change |
| |
|
2024 |
|
2023 |
|
2023-2024 |
| |
|
(U.S.$
in millions) |
|
|
| Europe segment |
|
|
|
|
|
|
|
|
| Generic products |
|
$ |
970 |
|
$ |
909 |
|
7% |
| AJOVY |
|
|
52 |
|
|
39 |
|
33% |
| COPAXONE |
|
|
53 |
|
|
60 |
|
(11%) |
| Respiratory products |
|
|
57 |
|
|
66 |
|
(14%) |
| Other |
|
|
81 |
|
|
89 |
|
(10%) |
| Total |
|
|
1,213 |
|
|
1,163 |
|
4% |
| |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
| |
|
Three
months ended |
|
|
| |
|
June
30, |
|
Percentage Change |
| |
|
2024 |
|
2023 |
|
2023-2024 |
| |
|
(U.S.$
in millions) |
|
|
| International Markets segment |
|
|
|
|
|
|
|
|
| Generic products |
|
$ |
486 |
|
$ |
478 |
|
2% |
| AJOVY |
|
|
22 |
|
|
14 |
|
58% |
| COPAXONE |
|
|
14 |
|
|
17 |
|
(20%) |
| Other |
|
|
71 |
|
|
69 |
|
2% |
| Total |
|
|
593 |
|
|
578 |
|
3% |
| |
|
|
|
|
|
|
|
|
| Revenues by Activity and Geographical
Area |
| (Unaudited) |
| |
|
|
|
|
|
|
|
|
| |
|
Six
months ended |
|
|
| |
|
June
30, |
|
Percentage Change |
| |
|
2024 |
|
2023 |
|
2024-2023 |
| |
|
(U.S.$ in millions) |
|
|
| North America segment |
|
|
|
|
|
|
|
|
| Generic products |
|
$ |
1,831 |
|
$ |
1,631 |
|
12% |
| AJOVY |
|
|
87 |
|
|
98 |
|
(12%) |
| AUSTEDO |
|
|
689 |
|
|
478 |
|
44% |
| BENDEKA / TREANDA |
|
|
87 |
|
|
129 |
|
(33%) |
| COPAXONE |
|
|
111 |
|
|
127 |
|
(13%) |
| Anda |
|
|
754 |
|
|
816 |
|
(8%) |
| Other |
|
|
276 |
|
|
289 |
|
(4%) |
| Total |
|
|
3,835 |
|
|
3,569 |
|
7% |
| |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
| |
|
Six
months ended |
|
|
| |
|
June
30, |
|
Percentage Change |
| |
|
2024 |
|
2023 |
|
2024-2023 |
| |
|
(U.S.$
in millions) |
|
|
| Europe segment |
|
|
|
|
|
|
|
|
| Generic products |
|
$ |
1,974 |
|
$ |
1,841 |
|
7% |
| AJOVY |
|
|
102 |
|
|
74 |
|
37% |
| COPAXONE |
|
|
110 |
|
|
119 |
|
(7%) |
| Respiratory products |
|
|
123 |
|
|
134 |
|
(8%) |
| Other |
|
|
175 |
|
|
178 |
|
(2%) |
| Total |
|
|
2,485 |
|
|
2,347 |
|
6% |
| |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
| |
|
Six
months ended |
|
|
| |
|
June
30, |
|
Percentage Change |
| |
|
2024 |
|
2023 |
|
2024-2023 |
| |
|
(U.S.$
in millions) |
|
|
| International Markets segment |
|
|
|
|
|
|
|
|
| Generic products |
|
$ |
963 |
|
$ |
955 |
|
1% |
| AJOVY |
|
|
39 |
|
|
27 |
|
42% |
| COPAXONE |
|
|
25 |
|
|
34 |
|
(26%) |
| Other |
|
|
162 |
|
|
142 |
|
14% |
| Total |
|
|
1,190 |
|
|
1,159 |
|
3% |
| |
|
|
|
|
|
|
|
|
| Free cash flow reconciliation |
| (Unaudited) |
| |
|
|
|
|
|
|
|
| |
Three
months ended June 30, |
| |
2024 |
|
2023 |
| |
|
|
|
|
|
|
|
| |
(U.S. $ in millions) |
| |
|
|
|
|
|
|
|
| Net cash provided by (used in) operating activities |
|
103 |
|
|
|
324 |
|
| Beneficial interest collected in exchange for securitized
accounts receivables |
|
317 |
|
|
|
371 |
|
| Capital investment |
|
(97 |
) |
|
|
(119 |
) |
| Proceeds from divestitures of businesses and other assets |
|
1 |
|
|
|
56 |
|
| Free cash flow |
$ |
324 |
|
|
$ |
632 |
|
| |
|
|
|
|
|
|
|
| Free cash flow reconciliation |
| (Unaudited) |
| |
|
|
|
|
|
|
|
| |
Six
months ended June 30, |
| |
2024 |
|
2023 |
| |
|
|
|
|
|
|
|
| |
(U.S. $ in millions) |
| |
|
|
|
|
|
|
|
| Net cash provided by (used in) operating activities |
|
(21 |
) |
|
|
179 |
|
| Beneficial interest collected in exchange for securitized
trade receivables |
|
612 |
|
|
|
694 |
|
| Capital investment |
|
(221 |
) |
|
|
(258 |
) |
| Proceeds from divestitures of business and other assets |
|
1 |
|
|
|
58 |
|
| Acquisition of subsidiary, net of cash acquired |
|
(15 |
) |
|
|
- |
|
| Free cash flow |
$ |
356 |
|
|
$ |
673 |
|
| |
|
|
|
|
|
|
|
IR Contacts
Ran Meir (215) 591-8912
Yael Ashman +972 (3) 914 8262
Sanjeev Sharma (267) 658-2700
PR Contacts
Kelley Dougherty (973) 832-2810
Eden Klein +972 (3) 906 2645
A PDF accompanying this announcement is available at: http://ml-eu.globenewswire.com/Resource/Download/3b1553b7-359d-4dae-86c1-9fe532ff3836
v3.24.2
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionISO 3166-1 alpha-2 country code.
| Name: |
dei_EntityAddressCountry |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:countryCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Nov 2024 to Dec 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Dec 2023 to Dec 2024
